Three years of experience: The italian registry and safety data update

G. L. Mancardi, G. Tedeschi, M. P. Amato, R. D'Alessandro, F. Drago, C. Milanese, P. Popoli, P. Rossi, G. Savettieri, M. R. Tola, G. Comi, C. Pozzilli, A. Bertolotto, M. G. Marrosu, L. M E Grimaldi, A. Laroni, N. Vanacore, A. Covezzoli, M. De Rosa, C. PiccinniN. Montanaro, L. Periotto, R. Iommelli, C. Tomino, L. Provinciali

Research output: Contribution to journalArticle

Abstract

At the end of 2006, a pharmacovigilance program on natalizumab was settled by the Italian Pharmaceutical Agency, and on January 2007, multiple sclerosis patients poorly responding to the immunomodulating therapies or with an aggressive clinical form of disease from onset initiated to be registered and to receive the medication. On February 2010, almost 3,000 cases have been treated with natalizumab. The drop-out rate is 10%. Almost 800 cases received cycles of natalizumab for more than 18 months. One case of PML was reported and other adverse events are similar to those described in phase III studies. The majority of cases remained stable, while in 25% of cases, an improvement of disability was documented.

Original languageEnglish
JournalNeurological Sciences
Volume31
Issue numberSUPPL. 3
DOIs
Publication statusPublished - 2011

Fingerprint

Registries
Safety
Pharmacovigilance
Multiple Sclerosis
Pharmaceutical Preparations
Natalizumab
Therapeutics

Keywords

  • Multiple sclerosis
  • Natalizumab
  • Pharmacovigilance
  • Surveillance program

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology
  • Medicine(all)

Cite this

Mancardi, G. L., Tedeschi, G., Amato, M. P., D'Alessandro, R., Drago, F., Milanese, C., ... Provinciali, L. (2011). Three years of experience: The italian registry and safety data update. Neurological Sciences, 31(SUPPL. 3). https://doi.org/10.1007/s10072-010-0356-8

Three years of experience : The italian registry and safety data update. / Mancardi, G. L.; Tedeschi, G.; Amato, M. P.; D'Alessandro, R.; Drago, F.; Milanese, C.; Popoli, P.; Rossi, P.; Savettieri, G.; Tola, M. R.; Comi, G.; Pozzilli, C.; Bertolotto, A.; Marrosu, M. G.; Grimaldi, L. M E; Laroni, A.; Vanacore, N.; Covezzoli, A.; De Rosa, M.; Piccinni, C.; Montanaro, N.; Periotto, L.; Iommelli, R.; Tomino, C.; Provinciali, L.

In: Neurological Sciences, Vol. 31, No. SUPPL. 3, 2011.

Research output: Contribution to journalArticle

Mancardi, GL, Tedeschi, G, Amato, MP, D'Alessandro, R, Drago, F, Milanese, C, Popoli, P, Rossi, P, Savettieri, G, Tola, MR, Comi, G, Pozzilli, C, Bertolotto, A, Marrosu, MG, Grimaldi, LME, Laroni, A, Vanacore, N, Covezzoli, A, De Rosa, M, Piccinni, C, Montanaro, N, Periotto, L, Iommelli, R, Tomino, C & Provinciali, L 2011, 'Three years of experience: The italian registry and safety data update', Neurological Sciences, vol. 31, no. SUPPL. 3. https://doi.org/10.1007/s10072-010-0356-8
Mancardi GL, Tedeschi G, Amato MP, D'Alessandro R, Drago F, Milanese C et al. Three years of experience: The italian registry and safety data update. Neurological Sciences. 2011;31(SUPPL. 3). https://doi.org/10.1007/s10072-010-0356-8
Mancardi, G. L. ; Tedeschi, G. ; Amato, M. P. ; D'Alessandro, R. ; Drago, F. ; Milanese, C. ; Popoli, P. ; Rossi, P. ; Savettieri, G. ; Tola, M. R. ; Comi, G. ; Pozzilli, C. ; Bertolotto, A. ; Marrosu, M. G. ; Grimaldi, L. M E ; Laroni, A. ; Vanacore, N. ; Covezzoli, A. ; De Rosa, M. ; Piccinni, C. ; Montanaro, N. ; Periotto, L. ; Iommelli, R. ; Tomino, C. ; Provinciali, L. / Three years of experience : The italian registry and safety data update. In: Neurological Sciences. 2011 ; Vol. 31, No. SUPPL. 3.
@article{a68cce98024f4a39bfc30596f134972c,
title = "Three years of experience: The italian registry and safety data update",
abstract = "At the end of 2006, a pharmacovigilance program on natalizumab was settled by the Italian Pharmaceutical Agency, and on January 2007, multiple sclerosis patients poorly responding to the immunomodulating therapies or with an aggressive clinical form of disease from onset initiated to be registered and to receive the medication. On February 2010, almost 3,000 cases have been treated with natalizumab. The drop-out rate is 10{\%}. Almost 800 cases received cycles of natalizumab for more than 18 months. One case of PML was reported and other adverse events are similar to those described in phase III studies. The majority of cases remained stable, while in 25{\%} of cases, an improvement of disability was documented.",
keywords = "Multiple sclerosis, Natalizumab, Pharmacovigilance, Surveillance program",
author = "Mancardi, {G. L.} and G. Tedeschi and Amato, {M. P.} and R. D'Alessandro and F. Drago and C. Milanese and P. Popoli and P. Rossi and G. Savettieri and Tola, {M. R.} and G. Comi and C. Pozzilli and A. Bertolotto and Marrosu, {M. G.} and Grimaldi, {L. M E} and A. Laroni and N. Vanacore and A. Covezzoli and {De Rosa}, M. and C. Piccinni and N. Montanaro and L. Periotto and R. Iommelli and C. Tomino and L. Provinciali",
year = "2011",
doi = "10.1007/s10072-010-0356-8",
language = "English",
volume = "31",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Three years of experience

T2 - The italian registry and safety data update

AU - Mancardi, G. L.

AU - Tedeschi, G.

AU - Amato, M. P.

AU - D'Alessandro, R.

AU - Drago, F.

AU - Milanese, C.

AU - Popoli, P.

AU - Rossi, P.

AU - Savettieri, G.

AU - Tola, M. R.

AU - Comi, G.

AU - Pozzilli, C.

AU - Bertolotto, A.

AU - Marrosu, M. G.

AU - Grimaldi, L. M E

AU - Laroni, A.

AU - Vanacore, N.

AU - Covezzoli, A.

AU - De Rosa, M.

AU - Piccinni, C.

AU - Montanaro, N.

AU - Periotto, L.

AU - Iommelli, R.

AU - Tomino, C.

AU - Provinciali, L.

PY - 2011

Y1 - 2011

N2 - At the end of 2006, a pharmacovigilance program on natalizumab was settled by the Italian Pharmaceutical Agency, and on January 2007, multiple sclerosis patients poorly responding to the immunomodulating therapies or with an aggressive clinical form of disease from onset initiated to be registered and to receive the medication. On February 2010, almost 3,000 cases have been treated with natalizumab. The drop-out rate is 10%. Almost 800 cases received cycles of natalizumab for more than 18 months. One case of PML was reported and other adverse events are similar to those described in phase III studies. The majority of cases remained stable, while in 25% of cases, an improvement of disability was documented.

AB - At the end of 2006, a pharmacovigilance program on natalizumab was settled by the Italian Pharmaceutical Agency, and on January 2007, multiple sclerosis patients poorly responding to the immunomodulating therapies or with an aggressive clinical form of disease from onset initiated to be registered and to receive the medication. On February 2010, almost 3,000 cases have been treated with natalizumab. The drop-out rate is 10%. Almost 800 cases received cycles of natalizumab for more than 18 months. One case of PML was reported and other adverse events are similar to those described in phase III studies. The majority of cases remained stable, while in 25% of cases, an improvement of disability was documented.

KW - Multiple sclerosis

KW - Natalizumab

KW - Pharmacovigilance

KW - Surveillance program

UR - http://www.scopus.com/inward/record.url?scp=82455185180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82455185180&partnerID=8YFLogxK

U2 - 10.1007/s10072-010-0356-8

DO - 10.1007/s10072-010-0356-8

M3 - Article

C2 - 20644975

AN - SCOPUS:82455185180

VL - 31

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - SUPPL. 3

ER -